Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Elaine Lam

Concepts (304)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
36
2025
217
7.170
 Why?
Kidney Neoplasms
39
2025
403
6.660
 Why?
Prostatic Neoplasms
13
2023
1043
2.910
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
77
1.500
 Why?
Antineoplastic Agents
15
2024
2129
1.360
 Why?
Prostate-Specific Antigen
4
2023
162
1.200
 Why?
Antibodies, Monoclonal, Humanized
11
2025
804
1.190
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1692
1.100
 Why?
Neoplasms
10
2023
2671
0.980
 Why?
Testicular Neoplasms
3
2023
110
0.940
 Why?
Protein Kinase Inhibitors
11
2021
916
0.940
 Why?
Neoplasms, Unknown Primary
1
2025
19
0.940
 Why?
Antineoplastic Agents, Immunological
2
2025
190
0.890
 Why?
Carcinoma, Transitional Cell
4
2025
71
0.830
 Why?
Seminoma
2
2021
20
0.820
 Why?
Carcinoma, Medullary
2
2013
17
0.750
 Why?
Aged
36
2025
23961
0.730
 Why?
Retroperitoneal Neoplasms
1
2021
25
0.710
 Why?
Male
59
2025
67762
0.700
 Why?
Urinary Bladder Neoplasms
4
2025
252
0.690
 Why?
Pneumocystis carinii
1
2020
12
0.660
 Why?
Teratoma
1
2021
114
0.660
 Why?
Spinal Cord Compression
1
2020
20
0.660
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
42
0.650
 Why?
Pneumonia, Pneumocystis
1
2020
38
0.650
 Why?
Carcinoma, Squamous Cell
1
2025
683
0.640
 Why?
Humans
86
2025
137585
0.610
 Why?
Euterpe
1
2018
4
0.600
 Why?
Middle Aged
38
2025
33479
0.570
 Why?
Pyrazoles
3
2022
423
0.570
 Why?
TWEAK Receptor
1
2017
5
0.570
 Why?
Prednisone
3
2020
240
0.560
 Why?
Sulfonamides
3
2015
513
0.540
 Why?
Abiraterone Acetate
1
2017
14
0.530
 Why?
Biomarkers, Tumor
6
2025
1276
0.530
 Why?
Aged, 80 and over
17
2025
7635
0.520
 Why?
Plant Extracts
1
2018
202
0.510
 Why?
Pyridines
4
2021
506
0.500
 Why?
Adrenal Cortex Hormones
1
2020
565
0.500
 Why?
Antineoplastic Agents, Hormonal
2
2015
161
0.490
 Why?
Neoplasm Recurrence, Local
3
2023
1079
0.480
 Why?
Neoplasm Metastasis
9
2020
658
0.480
 Why?
Carcinoma, Papillary
1
2015
81
0.470
 Why?
Brain Neoplasms
2
2021
1238
0.460
 Why?
Patient Reported Outcome Measures
4
2025
402
0.450
 Why?
Everolimus
2
2025
91
0.450
 Why?
Paclitaxel
3
2022
230
0.440
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
51
0.430
 Why?
Neoplasms, Complex and Mixed
1
2013
8
0.420
 Why?
Interleukin-2
2
2014
455
0.420
 Why?
Antibodies, Monoclonal
2
2017
1430
0.410
 Why?
Urologic Neoplasms
2
2025
31
0.390
 Why?
Treatment Outcome
17
2025
10811
0.390
 Why?
Retrospective Studies
18
2024
15657
0.390
 Why?
Nephrectomy
4
2024
169
0.380
 Why?
Epothilones
1
2011
1
0.370
 Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1081
0.370
 Why?
Androgen Antagonists
3
2020
82
0.360
 Why?
Basic Helix-Loop-Helix Transcription Factors
3
2024
243
0.360
 Why?
Angiomyolipoma
1
2011
24
0.360
 Why?
Deoxycytidine
2
2010
179
0.350
 Why?
Multicenter Studies as Topic
1
2012
310
0.350
 Why?
Anilides
4
2021
73
0.350
 Why?
Adult
27
2025
37929
0.340
 Why?
Benzenesulfonates
1
2010
22
0.330
 Why?
Lung Neoplasms
4
2025
2526
0.330
 Why?
Suramin
1
2010
8
0.330
 Why?
Radiosurgery
3
2019
344
0.310
 Why?
Maximum Tolerated Dose
6
2022
199
0.310
 Why?
Female
34
2025
73304
0.300
 Why?
Immunotherapy
5
2024
641
0.290
 Why?
Indenes
2
2025
6
0.290
 Why?
Fluorouracil
1
2008
208
0.280
 Why?
Disease Progression
3
2021
2757
0.280
 Why?
Bone Neoplasms
2
2023
247
0.270
 Why?
Quinazolines
1
2008
251
0.270
 Why?
Chemotherapy, Adjuvant
3
2013
389
0.260
 Why?
Neoplasm Staging
7
2017
1389
0.260
 Why?
Practice Guidelines as Topic
4
2024
1587
0.260
 Why?
Platinum
2
2024
50
0.250
 Why?
Drug Administration Schedule
3
2021
786
0.250
 Why?
Thyroid Neoplasms
1
2010
343
0.240
 Why?
B7-H1 Antigen
2
2025
217
0.240
 Why?
Sulfones
2
2017
110
0.240
 Why?
Prognosis
5
2023
4030
0.240
 Why?
Microsatellite Instability
1
2025
42
0.230
 Why?
Phenylurea Compounds
4
2016
97
0.230
 Why?
Ipilimumab
2
2021
33
0.220
 Why?
Benzoxazoles
2
2022
19
0.210
 Why?
Taxoids
2
2017
102
0.210
 Why?
Melanoma
2
2025
760
0.210
 Why?
Bevacizumab
2
2020
138
0.200
 Why?
Multiple Sclerosis
2
2019
455
0.200
 Why?
Kaplan-Meier Estimate
5
2024
889
0.190
 Why?
Mastectomy
1
2023
137
0.190
 Why?
Pyrimidines
3
2022
470
0.190
 Why?
Quantitative Trait Loci
1
2024
380
0.180
 Why?
Remission, Spontaneous
1
2021
40
0.180
 Why?
Administration, Oral
4
2024
816
0.180
 Why?
Biliary Tract Neoplasms
1
2021
30
0.170
 Why?
Celecoxib
2
2012
39
0.170
 Why?
Bariatric Surgery
1
2024
217
0.170
 Why?
Carboplatin
1
2021
144
0.170
 Why?
Quality of Life
2
2025
2892
0.170
 Why?
Neoplasm, Residual
1
2021
133
0.170
 Why?
Phosphatidylinositol 3-Kinases
1
2022
366
0.170
 Why?
Syndrome
1
2021
358
0.170
 Why?
Proto-Oncogene Proteins c-akt
1
2022
437
0.170
 Why?
Combined Modality Therapy
4
2019
1236
0.170
 Why?
Azepines
1
2020
90
0.160
 Why?
Genomics
1
2025
795
0.160
 Why?
Cancer Care Facilities
1
2020
38
0.160
 Why?
Antiemetics
1
2020
43
0.160
 Why?
TOR Serine-Threonine Kinases
1
2022
412
0.160
 Why?
Thrombosis
1
2023
371
0.160
 Why?
Homologous Recombination
1
2019
28
0.160
 Why?
Fatal Outcome
1
2020
303
0.150
 Why?
Morpholines
1
2020
122
0.150
 Why?
Anti-Bacterial Agents
2
2020
1809
0.150
 Why?
MAP Kinase Kinase Kinases
1
2019
73
0.150
 Why?
Streptococcus
1
2019
28
0.150
 Why?
Pharyngitis
1
2019
26
0.150
 Why?
Disease-Free Survival
4
2016
686
0.150
 Why?
Fruit and Vegetable Juices
1
2018
15
0.150
 Why?
Feedback
1
2019
173
0.150
 Why?
Drug Hypersensitivity
1
2020
90
0.150
 Why?
Diagnosis, Computer-Assisted
1
2019
89
0.150
 Why?
Mutation
2
2025
3958
0.140
 Why?
Cost-Benefit Analysis
1
2021
591
0.140
 Why?
Indans
1
2017
11
0.140
 Why?
Neoplastic Cells, Circulating
2
2016
80
0.140
 Why?
Interferon beta-1b
1
2017
2
0.140
 Why?
Niacinamide
3
2016
82
0.140
 Why?
Liver Neoplasms
1
2023
786
0.130
 Why?
Genome-Wide Association Study
1
2024
1431
0.130
 Why?
Proton Therapy
1
2017
13
0.130
 Why?
Erythrocytes, Abnormal
1
2016
12
0.130
 Why?
Streptococcal Infections
1
2019
151
0.130
 Why?
Neoadjuvant Therapy
2
2023
404
0.130
 Why?
DNA Damage
1
2019
420
0.130
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
76
0.130
 Why?
Hematologic Diseases
1
2016
62
0.130
 Why?
Dose-Response Relationship, Drug
3
2022
2057
0.130
 Why?
Cell Line, Tumor
3
2020
3412
0.130
 Why?
Polymorphism, Single Nucleotide
1
2024
2189
0.130
 Why?
Oncolytic Virotherapy
1
2015
14
0.120
 Why?
Indazoles
2
2015
69
0.120
 Why?
Problem Solving
1
2017
152
0.120
 Why?
Autoimmune Diseases
1
2020
460
0.120
 Why?
Mammalian orthoreovirus 3
1
2015
37
0.120
 Why?
Pyrroles
1
2016
213
0.120
 Why?
Angiopoietin-1
1
2015
11
0.120
 Why?
Angiopoietin-2
1
2015
16
0.120
 Why?
Fatigue
2
2022
329
0.120
 Why?
Genetic Predisposition to Disease
1
2024
2426
0.120
 Why?
Receptor, IGF Type 1
1
2015
65
0.120
 Why?
Nanoparticles
1
2021
481
0.120
 Why?
Imidazoles
2
2015
238
0.120
 Why?
Kidney Glomerulus
1
2015
119
0.110
 Why?
Radiation Tolerance
1
2015
96
0.110
 Why?
Soft Tissue Neoplasms
1
2015
115
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
267
0.110
 Why?
Magnetic Resonance Imaging
2
2021
3566
0.110
 Why?
Severity of Illness Index
2
2019
2828
0.110
 Why?
Prefrontal Cortex
1
2017
301
0.110
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
108
0.100
 Why?
Indoles
1
2016
412
0.100
 Why?
Prostatectomy
1
2013
104
0.100
 Why?
Patient Satisfaction
1
2017
660
0.100
 Why?
Glycine
1
2014
176
0.100
 Why?
Cohort Studies
5
2021
5742
0.100
 Why?
Recombinant Fusion Proteins
1
2015
665
0.100
 Why?
Quinolines
1
2013
178
0.090
 Why?
Tubulin Modulators
1
2011
10
0.090
 Why?
Glomerular Filtration Rate
1
2015
746
0.090
 Why?
Emotions
1
2017
548
0.090
 Why?
Metabolic Clearance Rate
1
2011
115
0.090
 Why?
Algorithms
1
2019
1704
0.090
 Why?
Arthralgia
1
2011
56
0.090
 Why?
Area Under Curve
1
2011
314
0.090
 Why?
Clinical Trials as Topic
1
2015
1050
0.090
 Why?
Breast Neoplasms
1
2023
2253
0.090
 Why?
Peripheral Nervous System Diseases
1
2011
128
0.080
 Why?
Diarrhea
1
2011
184
0.080
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
125
0.080
 Why?
Proto-Oncogene Proteins c-ret
1
2010
36
0.080
 Why?
Molecular Structure
1
2011
489
0.080
 Why?
Survival Rate
3
2020
1972
0.080
 Why?
Biopsy
1
2013
1129
0.080
 Why?
Decision Making
1
2017
900
0.080
 Why?
Tomography, X-Ray Computed
3
2022
2691
0.080
 Why?
Nomograms
1
2010
54
0.080
 Why?
Radiotherapy, Adjuvant
1
2010
220
0.080
 Why?
Immunohistochemistry
1
2013
1738
0.080
 Why?
Drug Synergism
1
2010
382
0.080
 Why?
Capecitabine
1
2008
45
0.080
 Why?
Infusions, Intravenous
1
2010
413
0.080
 Why?
Positron-Emission Tomography
1
2010
294
0.070
 Why?
Proteinuria
1
2008
97
0.070
 Why?
Hypertension, Pregnancy-Induced
1
2008
69
0.070
 Why?
Young Adult
4
2024
13209
0.060
 Why?
Follow-Up Studies
3
2020
5131
0.060
 Why?
Creatinine
1
2008
499
0.060
 Why?
Risk
1
2008
912
0.060
 Why?
Optical Illusions
1
2005
2
0.060
 Why?
Urothelium
1
2025
37
0.060
 Why?
Risk Factors
2
2020
10388
0.060
 Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
16
0.060
 Why?
Cytoreduction Surgical Procedures
1
2024
63
0.050
 Why?
Prospective Studies
3
2021
7604
0.050
 Why?
Mastectomy, Segmental
1
2023
93
0.050
 Why?
Adjuvants, Immunologic
1
2024
226
0.050
 Why?
RNA Interference
1
2024
469
0.050
 Why?
Cardiovascular Diseases
1
2014
2111
0.050
 Why?
Disease Management
2
2017
628
0.050
 Why?
RNA, Small Interfering
1
2024
622
0.050
 Why?
Cisplatin
1
2023
320
0.040
 Why?
Nephritis, Interstitial
1
2020
14
0.040
 Why?
International Agencies
1
2020
35
0.040
 Why?
Aurora Kinase A
1
2020
56
0.040
 Why?
Drug Evaluation
1
2020
84
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
 Why?
Lymphocytes
1
2022
397
0.040
 Why?
Nausea
1
2020
111
0.040
 Why?
Medical Oncology
1
2022
289
0.040
 Why?
Hong Kong
1
2019
7
0.040
 Why?
Analysis of Variance
2
2017
1316
0.040
 Why?
Time Factors
1
2010
6828
0.040
 Why?
Vomiting
1
2020
130
0.040
 Why?
Sex Factors
1
2025
2071
0.040
 Why?
Lymphatic Metastasis
1
2020
352
0.040
 Why?
Hospitals
1
2023
691
0.040
 Why?
Central Nervous System
1
2020
258
0.040
 Why?
United States
2
2017
14841
0.030
 Why?
Databases, Factual
1
2023
1357
0.030
 Why?
Genetic Testing
1
2020
460
0.030
 Why?
Retreatment
1
2017
72
0.030
 Why?
Xenograft Model Antitumor Assays
1
2020
872
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
49
0.030
 Why?
Drug Therapy, Combination
1
2020
1066
0.030
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
234
0.030
 Why?
Erythrocyte Indices
1
2016
30
0.030
 Why?
Academic Medical Centers
1
2020
512
0.030
 Why?
Antimicrobial Stewardship
1
2019
118
0.030
 Why?
Clinical Decision-Making
1
2019
322
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
250
0.030
 Why?
Anti-Inflammatory Agents
1
2020
496
0.030
 Why?
Case-Control Studies
1
2024
3556
0.030
 Why?
Neutrophils
1
2022
1238
0.030
 Why?
Acute Disease
1
2019
1007
0.030
 Why?
Abdominal Neoplasms
1
2015
39
0.030
 Why?
Thoracic Neoplasms
1
2015
37
0.030
 Why?
Tosyl Compounds
1
2015
15
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Reaction Time
1
2017
412
0.030
 Why?
Kidney Function Tests
1
2015
160
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
801
0.030
 Why?
Angiogenesis Inhibitors
1
2016
229
0.030
 Why?
Craniocerebral Trauma
1
2017
170
0.030
 Why?
Neoplasm Grading
1
2015
307
0.030
 Why?
Radiotherapy
1
2015
201
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
130
0.030
 Why?
Organ Size
1
2015
477
0.030
 Why?
Postoperative Period
1
2015
342
0.030
 Why?
Demography
1
2015
291
0.030
 Why?
Nitriles
1
2015
172
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
142
0.030
 Why?
STAT5 Transcription Factor
1
2014
57
0.030
 Why?
Recurrence
1
2017
1060
0.030
 Why?
Drug Interactions
1
2015
410
0.030
 Why?
Medication Adherence
1
2017
467
0.030
 Why?
Gonadotropin-Releasing Hormone
1
2015
212
0.030
 Why?
Longitudinal Studies
1
2020
2844
0.020
 Why?
ErbB Receptors
1
2015
614
0.020
 Why?
Neuropsychological Tests
1
2017
1023
0.020
 Why?
Proportional Hazards Models
1
2015
1266
0.020
 Why?
Cell Survival
1
2015
1120
0.020
 Why?
Double-Blind Method
1
2016
1993
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
385
0.020
 Why?
Molecular Targeted Therapy
1
2014
411
0.020
 Why?
Biomarkers
1
2022
4149
0.020
 Why?
Enzyme Inhibitors
1
2014
840
0.020
 Why?
Proto-Oncogene Proteins
1
2014
648
0.020
 Why?
Cell Cycle Proteins
1
2014
617
0.020
 Why?
Logistic Models
1
2015
2074
0.020
 Why?
Reagent Strips
1
2008
8
0.020
 Why?
Primary Health Care
1
2019
1738
0.020
 Why?
Urinalysis
1
2008
77
0.020
 Why?
Albuminuria
1
2008
185
0.020
 Why?
Diagnostic Tests, Routine
1
2008
110
0.020
 Why?
Vision, Monocular
1
2005
4
0.010
 Why?
Psychophysics
1
2005
15
0.010
 Why?
Eye Enucleation
1
2005
12
0.010
 Why?
Vision, Binocular
1
2005
21
0.010
 Why?
Adolescent
2
2020
21513
0.010
 Why?
Orientation
1
2005
48
0.010
 Why?
Animals
2
2020
36940
0.010
 Why?
Pattern Recognition, Visual
1
2005
101
0.010
 Why?
Photic Stimulation
1
2005
241
0.010
 Why?
Sensitivity and Specificity
1
2008
1946
0.010
 Why?
Mice
1
2020
17787
0.010
 Why?
Signal Transduction
1
2014
5079
0.010
 Why?
Pregnancy
1
2008
6763
0.010
 Why?
Child
1
2005
21935
0.000
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (304) concept(s)
_
Co-Authors Expand Description
See all (51) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)